



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 January 2024  
European Medicines Agency

## Agenda — Medicine Shortages (SPOC) Working Party

21 January 2025, from 09:30 to 13:30 (CET), Webex

**Chair: Monica Dias (EMA), Vice-Chair: Magdalena Rychter (GIF, Poland)**

Item	Topic
1.	Welcome, declaration of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 5 December 2024
3.	<b>Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)</b> -led activities:
	a) Feedback from the MSSG meeting on 11 December 2024
	b) Voluntary Solidarity Mechanism (VSM): Presentation of the latest VSM procedure
	c) MSSG Working Group on the Vulnerability Assessment Methodology
4.	Joint Action on shortages ( <b>CHESSMEN</b> ) <ul style="list-style-type: none"><li>• Latest findings</li><li>• Outcome of the multistakeholder workshop</li></ul>
5.	<b>Potential impact of the international situation</b> on the supply of medicinal products for human and veterinary use to the European market:
	a) Availability of antibiotics – preparedness for autumn/winter 2024-2025
	b) Availability of perfusion solutions following hurricane Helene
	c) Oral status update on availability of human and veterinary medicines in MSs (only for new emerging information)
6.	<b>Critical shortages escalated to the SPOC Working Party:</b>
6.1	<b>Ongoing shortages:</b>
	a) NovoSeven CAP (eptacog alfa) – MAH: Novo Nordisk

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Topic
	b) Availability issues of Teva medicines: <ul style="list-style-type: none"> <li>Overview of the overall shortage situation</li> <li>Presentation delivered by MAH: Teva, followed by a Q&amp;A session</li> <li>Debrief on next steps/actions</li> </ul>
	c) Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
	d) Insulin containing medicinal products
6.2	<b>Status update on other critical shortages escalated to the SPOC WP</b> (only comments to the written updates):
	a) Pegasys CAP (peginterferon alfa-2a) – MAH: Pharmaand GmbH b) Medicinal products from MAH: Cheplapharm c) Medicinal products containing salbutamol (inhalation use) d) Oncology medicinal products from Accord Healthcare B.V. e) Ecalta CAP (anidulafungin) and Zirabev CAP (bevacizumab) – MAH: Pfizer
7.	European Shortages Monitoring Platform ( <b>ESMP</b> ) update
8.	EC DG <b>HERA</b> update
9.	Conclusions and next steps

---

**Next meeting:** 18 February (Webex)

---

#### **Note on access to documents**

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).